ObjectiveTo explore the application value of repaglinide combined with metformin in type 2 diabetes therapy.Methóds92 patients with type 2 diabetes were randomly divided into study group and control group.Two groups of patients were given repaglinide treatment,patients in study group given metformin treatment.The blood lipid,glucose metabolism,body weight change and clinical outcomes were compared belween the groups.ResultsCompared with the control group,study group the cure rate and total effective rate was significantly increased,as high as 58.7％ and 97.8％,the ineffective rate was significantly decreased,only 2.2％,there were significant differences ( x2 =2.64,3.59,3.59,P ＜ 0.05 ).The fasting and 2h postprandial blood glucose and glycated hemoglobin and other indicators of glucose metabolism in the study group were significantly decreased,there were also significant differences(P ＜ 0.05 ).The triglycerides and cholesterol and other lipid levels and body mass index in the study group were significantly decreased,there were significant differences ( P ＜ 0.05 ).ConclusionRepaglinide combined with metformin in type 2 diabetes treatment was remarkable for type 2 diabetes to further improve the clinical efficacy.

Objective Quantifiably and located measure the methylation rate of 21 cytosinephosphate-guanosine (CpG) sites in the 3' region of L1 gene and long control region (LCR) gene of HPV16 DNA in asymptomatic patients,cervical intraepithelial neoplasia (CIN) patients,and cervical cancer patients.To analysis the relationship between HPV16 methylation and it's pathogenicity.Methods Chosen 30 cases with HPV16 positive in each group.Firstly,extract DNA from the remaining cells of liquid-based cytology specimen and bisulfite treatment DNA,then amplify the 3' region of L1 gene and LCR gene,test the methylation rate of 21 CpG sites of HPV16 DNA in three groups.Results All of the 5 CpG sites in E6/E7 promoter (31,37,43,52,58) were hypomethylation in cervical cancer group (21.86％,28.15％,21.37％,26.15％,15.48％,respectively),hypermethylation in asymptomatic group,and middle-methylation in CIN group,in which there were significant difference among three groups (all P ＜0.01).The CpG site in 7032,7091,7136 of the 3' region of L1 gene was also different methylated among three groups (all P＜0.01).Hypermethylation was found in cancer group (18.89％,27.72％),hypomethylation was found in asymptomatic group (2.71％,6.95％) in 7032 and 7091.In 7136,the highest methylation was detected in CIN (66.45％),the lowest in asymptomatic (34.85％),middle in cancer group (46.43％).Conclusion The methylation status of CpG sites in the 3' region of L1 gene and E6/E7 promoter of HPV16 is significant different among three groups,which is likely to anticipate the pathogenesis of CIN and cervical cancer.

AIM: To observe the effect of monoclonal antibody of epidermal growth factor receptor (EGFR) on human colon carcinoma cell lines. METHODS:Cell counting, growth curve measurement and MTT method were applied in this study to examine the proliferation of cultured cells in vitro when different dosage of EGFR McAb is used to treat LST174 colon carcinoma cell lines. RESULT: The proliferation of cultured human colon carcinoma cells could be significantly inhibited in a dose dependent manner by EGFR antibody Compared with the control group, the cell number was decreased by 61 3% and 33 8% respectively when treated with 0 625 mL/L or 2 5 mL/L of EGFR McAb CONCLUSION: EGFR McAb can inhibit cell growth of human colon carcinoma LST174.

There exists the contradiction between medical value and social ethics on human-body experiments,so the ethics requires that we should set a comprehesive appraise and choose the corresponding ethical principle to standardize the behavior of human-body experiments.

AIM: To study the effects of Shenghua Decoction on the expression of adhesion molecules in vascular endothelial cells (VECs) of blood-stasis rats. METHODS: The expression of VCAM-1, ICAM-1, PECAM-1, iNOS and their corresponding mRNA in VECs were assayed by immunohistochemistry, image analysis and RT-PCR under the function of different Shenghua Decoction doses (high, middle, low). RESULTS: Immunohistochemistry and image analysis indicated: the expression of VCAM-1, ICAM-1, PECAM-1 and iNOS were higher in the model group than in the control group, Shenghua Decoction could decrease the expression of VCAM-1, ICAM-1, PECAM-1 and iNOS in the model group, moreover as the dose decreased, the expression of these molecules increase, it was of dose-effect relation. CONCLUSION: Shenghua Decoction can downregulate the expression of adhesion molecules in vascular endothelial cells of blood-stasis rats, and the dose-effect relation is obvious.

Objective To explore emergency treatment strategies for the patients with brain hernia combined with hemorrhagic shock after severe traumatic brain injury and their effect on prognosis.Methods A retrospective analysis was made on 54 patients (study group) with brain hernia combined with hemorrhagic shock treated with selective treatment strategies from May 2006 to May 2009. Another 48 patients with the same injuries treated with no selective treatment strategies from April 2003 to April 2006 were used as control group. The mortality within one week and the GOS six months after injury were compared in two groups. Results There was no statistical difference in aspects of sex, age, injury mechanism, GCS and blood loss in both groups (P＞0.05). Thirteen patients died in the study group within the first week, with mortality rate of 24.1%. While 16 patients died in the control group at the first week, with mortality rate of 33.3% (P＜0.05). GOS half year after injury in the study group was better than that in the control group (P＜0.05).Conclusion Early selective treatment strategy based on degree of shock may obtain better outcome for patients with brain hernia combined with hemorrhagic shock after severe brain injury.

Objective To observe the relationship between short-term heart rate variability(HRV) and heart rate recovery (HRR) after exercise.Methods 495 patients (273 men),whose age ranged 19-85 years,were submitted to treadmill exercise tests and short-term HRV evaluations.The standard deviation of the normal-to-normal interval (SDNN),the square root of the mean squared differences of successive normal-to-normal intervals (RMSSD),the number of interval differences of successive normal-to-normal intervals greater than 50 ms (NN50 count),the proportion derived by dividing NN50 count by the total number of normal-to-normal intervals (pNN50) and frequency(lowfrequency power,high-frequency power,total power) domains were observed.Results Among 495 patients,106 patients(68 men) were elderly(age≥65 years).Male gender and hypertension were significantly higher in elderly patients.The young patients had higher HRR after exercise.HRR at 4min (54 ± 13) vs (60 ± 12) beats/min,P =0.003 was the most significant predictor for positive exercise test result.In the young group,both time domain measures (SDNN:correlation coefficient 0.34,P ＜ 0.001 ; RMSSD:correlation coefficient 0.37,P ＜ 0.001) and frequency domain measures (LF:correlation coefficient 0.21,P ＜ 0.001 ; HF:correlation coefficient 0.13,P =0.01 ; total power:correlation coefficient 0.22,P ＜ 0.001) were significantly associated with HRR at 4min.Conclusion HRR at 4min was significantly associated with short-term HRV of time and frequency domains in young individuals,but not elderly ones,who received treadmill exercise test.

Objective To establish the RP-HPLC method for the determination of myricetrin and quercitroside in Euphorbia Hirta L.Methods The ZORBAX SB-C18 (250 mm × 4.6 mm,5 μn) column was used,the mobile phase consisted of acetonitrile:0.1％ H3PO4(21 ∶ 79),the flow rate was 0.8 ml/min,the column temperature was 30℃ the detecting wavelength was at 256 nm.Results The cablibration curve was linear within a range of 0.013～0.26 mg/ml and 0.008～0.16 mg/ml,the average recovery was 99.1％,98.9％and the RSD was 0.91％,1.55％,respectively.Conclusion The method is simple,repeatable and accurate,it can be applied in quantitative determination of myricetrin and quercitroside in Euphorbia Hirta L..

Background:The efficacy of traditional medicine on ulcerative colitis (UC) is often unsatisfactory, hence development of drug based on the pathogenic mechanism of UC becomes a hot topic in the research of UC.It has been revealed in recent studies that activation of nuclear factor-κB (NF-κB) is implicated as a key regulator in the immune and inflammatory responses in UC.Aims:To explore whether bortezomib, a potent proteasome inhibitor that inhibits NF-κB activation can be used for treatment of UC.Methods:Thirty-two BALB/c mice were used to induce acute experimental colitis by drinking 3%dextran sulfate sodium (DSS) freely for 7 days, and then randomly allocated into four groups injected intraperitoneally with 0.2 (low-dose group), 0.6 (medium-dose group), 1.0 mg/kg (high-dose group) bortezomib and normal saline (model control group), respectively.On the 7th day after treatment, the disease activity index (DAI) and histopathological change of colonic tissue were observed;the colitis-related parameters including peripheral blood hemoglobin (Hb), C-reactive protein (CRP) and colonic myeloperoxidase (MPO) activity were measured, and the nuclear translocation of NF-κB was assessed by electrophoretic mobility shift assay.Results:Compared with the model control group, the DAI, CRP, MPO activity, and injury score of colonic tissue were decreased gradually, and the Hb was increased gradually in mice treated with low-, medium-and high-dose bortezomib (P all <0.05).The efficacy of medium-and high-dose bortezomib was notable.In mice treated with medium-and high-dose bortezomib, nuclear translocation of NF-κB was inhibited obviously.Conclusions:Bortezomib can modulate the colonic inflammation in mice with experimental colitis by inhibiting NF-κB activation and subsequently improving the clinical manifestations, colitis-related parameters and tissue damage.Increasing the dosage of bortezomib in a safety range may enhance the treatment response.

Objective To explore the clinical efficacy and the dynamic changes of serum vascular endothelial growth factor(VEGF),connective tissue growth factor(CTGF),hypoxia inducible factor 1α(HIF-1α)and osteopontin(OPN)levels after transcatheter arterial chemoembolization(TACE)combined with sorafenib in the treatment of advanced hepatocarcinoma(HCC)patients.Methods A total of 113 HCC patients in Cancer Hospital of Taizhou,from September 2013 to December 2014 were elected and were randomly divided into control group(n=56)and experiment group(n=57)according to random number.Control group were treated with sorafenib and experiment group were treated with TACE combined with sorafenib.The serum VEGF,CTGF,HIF-1α and OPN levels were tested and compared using indirect ELISA method preoperative and postoperative 1,3,7 days and which were carried out Spearman correlation analysis.The long-term clinical efficacy and adverse reaction in two groups were statisticed.Results The serum VEGF,CTGF,HIF-1α and OPN levels of two groups postoperative 1 day increased than preoperative(P<0.05).From postoperative one to seven days,the serum VEGF,CTGF,HIF-1α and OPN levels of two groups present downward trend(P<0.05 or P<0.01),and there was significant difference between two groups(P<0.01).The level of HIF-1α significantly positive correlated with the levels of VEGF,CTGF and OPN(r=0.951,0.954,0.929,P<0.05).Compared with control group,the median survival time and 1-year-survival rate of experiment group increased significantly(P<0.01).The incidence of hand-foot reaction,alopecia and diarrhea in experiment group were higher than those in control group(P<0.05),while the others had no significant difference between two groups(P>0.05).Conclusion The levels of VEGF,CTGF,HIF-1α and OPN of HCC patients after treated with TACE combined with sorafenib are lower than that treated with TACE alone,Simultaneously,the survival is prolonged and adverse reactions don't increase.